UA103015C2 - Новые производные инсулина с чрезвычайно замедленным профилем время/действие - Google Patents

Новые производные инсулина с чрезвычайно замедленным профилем время/действие

Info

Publication number
UA103015C2
UA103015C2 UAA201009821A UAA201009821A UA103015C2 UA 103015 C2 UA103015 C2 UA 103015C2 UA A201009821 A UAA201009821 A UA A201009821A UA A201009821 A UAA201009821 A UA A201009821A UA 103015 C2 UA103015 C2 UA 103015C2
Authority
UA
Ukraine
Prior art keywords
amino acid
action profile
radical
novel insulin
delayed time
Prior art date
Application number
UAA201009821A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пауль ХАБЕРМАНН
Герхард ЗАЙПКЕ
Роланд КУРРЛЕ
Гюнтер Мюллер
Марк ЗОММЕРФЕЛЬД
Норберт Теннагельс
Георг ЧАНК
Ульрих ВЕРНЕР
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Priority claimed from PCT/EP2009/000017 external-priority patent/WO2009087081A2/de
Publication of UA103015C2 publication Critical patent/UA103015C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к новым аналогам инсулина с базальным профилем время/действие, которые отличаются тем, что а) конец В-цепи (В32) содержит амидированный лизин или амидированный аргинин, b) N-терминальный аминокислотный остаток инсулина А-цепи является лизиновым или аргининовым остатком, с) позиция аминокислоты А8 занята гистидиновым остатком, d) позиция аминокислоты А21 занята глициновым остатком, и e) одно или несколько замещений и/или присоединений отрицательно заряженных аминокислотных остатков проводят в позициях А5, А15, А18, В-1, В0, В1, В2, В3 и В4.
UAA201009821A 2008-01-09 2009-01-06 Новые производные инсулина с чрезвычайно замедленным профилем время/действие UA103015C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200810003568 DE102008003568A1 (de) 2008-01-09 2008-01-09 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PCT/EP2009/000017 WO2009087081A2 (de) 2008-01-09 2009-01-06 Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil

Publications (1)

Publication Number Publication Date
UA103015C2 true UA103015C2 (ru) 2013-09-10

Family

ID=40758369

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201009821A UA103015C2 (ru) 2008-01-09 2009-01-06 Новые производные инсулина с чрезвычайно замедленным профилем время/действие

Country Status (3)

Country Link
CR (1) CR11511A (ru)
DE (1) DE102008003568A1 (ru)
UA (1) UA103015C2 (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
US9138462B2 (en) 2009-07-31 2015-09-22 Sanofi-Aventis Deutschland Gmbh Prodrugs comprising an insulin linker conjugate
NZ597964A (en) 2009-07-31 2014-04-30 Sanofi Aventis Deutschland Long acting insulin composition
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
KR20140043709A (ko) 2011-01-20 2014-04-10 질랜드 파마 에이/에스 아실화 글루카곤 유사체와 인슐린 유사체의 조합
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
IN2014MN02304A (ru) 2012-05-03 2015-08-07 Zealand Pharma As
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
IN2015DN00544A (ru) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
GR1005153B (el) 1989-08-29 2006-03-13 The General Hospital Corporation Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE19947456A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
AU2006291780B2 (en) 2005-09-14 2011-12-08 F. Hoffmann-La Roche Ag Cleavage of precursors of insulins by a variant of trypsin

Also Published As

Publication number Publication date
CR11511A (es) 2010-09-13
DE102008003568A1 (de) 2009-07-16

Similar Documents

Publication Publication Date Title
TN2010000298A1 (en) Novel insulin derivatives having an extremely delayed time-action profile
UA103015C2 (ru) Новые производные инсулина с чрезвычайно замедленным профилем время/действие
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
NZ743910A (en) Purification of iduronate-2-sulfatase
PH12013501213A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
MX2015011243A (es) Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.
MX337038B (es) Co-antagonistas de receptor de glucagon/glp-1.
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
CA2651990C (en) Improved antimicrobial peptides
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
WO2010085700A3 (en) Treatment for obesity
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
NZ595242A (en) Improved anti-serum albumin binding variants
BR112014013367A2 (pt) polipeptídeo
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
WO2013151467A3 (ru) Способ получения рекомбинантного пептида и полученный пептид
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
BR112017019241A2 (pt) análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico
WO2011061720A3 (en) Viral citrullinated peptides and uses thereof
MX2010011055A (es) Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.
MY155338A (en) Novel insulin derivatives having an extremely delayed time-action profile
EA201101285A1 (ru) Антагонистические пептиды к frizzled-1 и frizzled-2 рецепторам
WO2010114909A8 (en) Sulfonyl-piperidin-4-yl methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
GR1006934B (el) Πεπτιδικα αναλογα της mbp83-99 με μαννανη για χρηση στην ανοσοθεραπεια της σκληρυνσης κατα πλακας